What type of study is this?

This is a Human Clinical Trial study (also classified as: Phase 2, Pre-Registered Trial).

What question did this study set out to answer?

To evaluate the efficacy and safety of azacitidine combined with dasatinib for maintenance therapy in high-risk AML patients.

December 8, 2025Blood

View Full Paper

Ask AI

Bookmark

Authors

Randomized trial shows improved overall survival with azacitidine and dasatinib maintenance in high-risk AML, suggesting a new treatment option.

To evaluate the efficacy and safety of azacitidine combined with dasatinib for maintenance therapy in high-risk AML patients.
Prospective, randomized phase II clinical trial
Patients aged 11 to 76 with intermediate-high risk AML
Comparison between azacitidine alone and azacitidine plus dasatinib
Primary endpoint was overall survival; secondary endpoints included disease-free survival and adverse events.
Median overall survival was 26 months in the azacitidine group; not reached in the azacitidine plus dasatinib group
Two-year overall survival rates were 90% for azacitidine plus dasatinib versus 79.5% for azacitidine alone
Disease-free survival did not significantly differ between groups
Higher rates of adverse events were observed in the azacitidine plus dasatinib group but with no serious non-hematological events.

Jinli Jian (2025) studied this question.

View Full Paper

Ask AI

Bookmark

Randomized trial shows improved overall survival with azacitidine and dasatinib maintenance in high-risk AML, suggesting a new treatment option.